PrintContact
 
  • Home
  • About Us
  • Sativex
  • R&D
  • Investors
  • Media
GW Pharmaceuticals

Meeting patients' needs...

Our vision

...is to be the global leader in prescription cannabinoid medicines, through the rapid cost-effective development of pharmaceutical products which address clear unmet patient needs.

 
PATIENTS

Therapeutic areas of focus, clinical trials and other information on Sativex...

Click here

 
MEDICAL PROFESSIONALS

Prescriber information, clinical publications and other information on Sativex...

Click here

 
MEDIA

Press releases, frequently asked questions and contact information for media enquiries...

Click here

 
INVESTORS

Share price, regulatory news, company presentations and other investor information..

Click here

 
 

Latest News

8 May 2012

Sativex® Mutual Recognition Procedure Closes with Recommendation for Approval in Ten European Countries

23 April 2012

Publication of full Sativex® phase IIb pain trial results in official journal of the American Pain Society

News archive

Sportlight

FSA Logo

Share
Fraud
Alert!

 

SHARE PRICE

GBp 74.50

-1.00p 18/05/201216:35 BST

 
 
 

© GW Pharmaceuticals 2011

  • Home
  • Sitemap
  • Accessibility
  • Disclosure & Disclaimer
  • Contact
  • Email Alerts
 

Website designed and developed by www.emperordesign.co.uk